Like Tarpeyo, Filspari has been granted accelerated approval on the strength of its ability to reduce protein levels in the urine of IgAN patients, and neither drug has yet been shown to slow ...
The company launched Filspari at a discount to Calliditas’ corticosteroid-based Tarpeyo (budesonide) therapy, which became the first FDA-approved therapy for IgAN in 2021 and made sales of $104 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback